Lupin Pithampur unit gets 2 USFDA observations
The inspection of the company's Pithampur Unit-I facility by the United States Food and Drug Administration (USFDA) has been completed, Lupin said in a filing to BSE.
New Delhi: Drug firm Lupin on Wednesday said the US health regulator has issued two observations after inspection of the company's Madhya Pradesh facility.
The inspection of the company's Pithampur Unit-I facility by the United States Food and Drug Administration (USFDA) has been completed, Lupin said in a filing to BSE.
The inspection carried out between February 3 and February 11, 2020, closed with two 483 observations, it added.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.
It notifies the company's management of objectionable conditions at the facility.
"We uphold the highest standards of quality and compliance across our manufacturing operations and are committed to consistently produce and distribute products of the highest quality," Lupin MD Nilesh Gupta said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd